Abstract
BACKGROUND: Breast cancer (BC) remains a leading cause of cancer-related mortality among women globally, with increasing incidence rates posing significant public health challenges. Recent advancements in artificial intelligence (AI) have revolutionized medical imaging, particularly in enhancing diagnostic accuracy and prognostic capabilities for BC. While multimodal imaging combined with AI has shown remarkable potential, a comprehensive analysis is needed to synthesize current research and identify emerging trends and hotspots in AI-assisted multimodal imaging for BC. METHODS: This study analyzed literature on AI-assisted multimodal imaging in BC from January 2010 to November 2024 in Web of Science Core Collection (WoSCC). Bibliometric and visualization tools, including VOSviewer, CiteSpace, and the Bibliometrix R package, were employed to assess countries, institutions, authors, journals, and keywords. RESULTS: A total of 80 publications were included, revealing a steady increase in annual publications and citations, with a notable surge post-2021. China led in productivity and citations, while Germany exhibited the highest citation average. The United States demonstrated the strongest international collaboration. The most productive institution and author are Radboud University Nijmegen and Xi, Xiaoming. Publications were predominantly published in Computerized Medical Imaging and Graphics, with Qian, XJ's 2021 study on BC risk prediction under deep learning frameworks being the most influential. Keyword analysis highlighted themes such as "breast cancer", "classification", and "deep learning". CONCLUSIONS: AI-assisted multimodal imaging has significantly advanced BC diagnosis and management, with promising future developments. This study offers researchers a comprehensive overview of current frameworks and emerging research directions. Future efforts are expected to focus on improving diagnostic precision and refining therapeutic strategies through optimized imaging techniques and AI algorithms, emphasizing international collaboration to drive innovation and clinical translation.